By October, the company should have the Back trial recruiting and running, and the GvHD adult trial up and running.
Assuming the other 4 applications all result in more trials required, and pediatric GVHD' s is rejected, which is the worst possible outcome in my opinion, mid 2025 we should have an idea if the trials are not able to make the end points or not.
Ann: Mesoblast 2024 Half Year Financial Results Webcast, page-62
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.01 |
Change
-0.065(6.07%) |
Mkt cap ! $1.147B | |||
| Open | High | Low | Value | Volume |
| $1.05 | $1.05 | 99.5¢ | $9.449M | 9.298M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 64999 | $1.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.02 | 64541 | 3 |
View Market Depth
| Last trade - 16.10pm 30/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |